

## ASX Announcement

1 June 2026

### Distribution agreement for broader Hong Kong market

#### Key Highlights

- Distribution agreement executed with Swedish Trading Company (STC), a leading medical device distributor headquartered in Hong Kong
- Agreement covers the Hong Kong, Macau and Greater China Bay Area markets, representing a combined addressable population of approximately 88 million people
- STC brings an established network of hospitals and surgeons across the region and a proven track record in commercialising innovative medical technologies
- Agreement structured as exclusive for an initial term of 3 years, with performance milestones and renewal options

**ReNerve Limited** (ASX, "ReNerve" or "the Company"), an Australian biotechnology company developing innovative products for peripheral nerve injury ("PNI") repair, announced today that it has partnered with Swedish Trading Company Limited ("STC") to commercialise ReNerve NervAlign products across Hong Kong, Macau and the Greater Bay Area, following the Company's recently announced expanded product approval across those jurisdictions.

Under the terms of the agreement, STC will be responsible for the importation, warehousing, marketing, sales and distribution of ReNerve within Hong Kong, Macau and the Greater Bay Area. ReNerve will provide ongoing clinical and technical support, training and regulatory liaison. ReNerve and STC are currently shipping the first stocking orders to the Hong Kong region.

*"Securing a distribution partner of STC's calibre is a significant milestone for ReNerve and a direct result of the expanded regulatory approval we recently received across the region. STC has deep relationships with key clinical networks and hospital systems across the region, and we believe they are the ideal partner to drive rapid and effective market penetration for ReNerve," said Dr Julian Chick, ReNerve CEO.*

*"The Greater Bay Area of Hong Kong represents one of the most dynamic and well-resourced healthcare markets in Asia, and this agreement positions us to capture meaningful commercial traction in a region where the unmet need in nerve repair is important for ReNerve.. We look forward to working closely with the STC team to bring ReNerve to patients across this region."*



+61 (03) 9482 3940



157 Heidelberg Rd,  
Northcote, VIC 3070



[www.renerve.com.au](http://www.renerve.com.au)

## About STC

STC is a Hong Kong-based distributor specialising in medical devices with an established commercial presence across Hong Kong region. STC represents many complementary international healthcare brands and maintains direct relationships with major hospital and clinical networks across the area<sup>1</sup>.

---

## Greater Bay Area Market Opportunity

The Guangdong–Hong Kong–Macau Greater Bay Area comprises 11 cities with a combined GDP of approximately USD 2 trillion and a population of over 88 million people<sup>2</sup>. The region has seen significant investment in healthcare infrastructure and is recognised as a priority market for innovative medical technologies under China's national health strategy.

- ENDS -

**This announcement has been approved for release by the Company's Board of Directors.**

**For further information and enquiries, please contact:**

**Dr Julian Chick**  
CEO & Managing Director  
ReNerve Ltd  
+61 (03) 9482 3940  
[info@renerve.com.au](mailto:info@renerve.com.au)

**Matthew Wright**  
Investor & Media Relations  
NWR Communications  
+61 (0) 451 896 420  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

---

<sup>1</sup> <https://www.swedishtrading.com/>

<sup>2</sup> <https://www.bayarea.gov.hk/en/about/overview.html>


## About ReNerve Limited (ASX:RNV)

ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.

### Proven Clinical Success

ReNerve's first flagship product, the FDA-cleared **NervAlign® Nerve Cuff**, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives.

### Comparison of Patient Pre & Post Surgery Pain Score



Standard of Care vs NervAlign™ Nerve Cuff Protected Nerve Repairs

The comparison of pain scores between the two cohorts of patients

For personal use only

## Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions and related surgical repairs:

### *On market*

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **Empliq™ Deep Dermal tissue product** -- A unique deep dermal product used in the repair of reconstructive and cosmetic surgical cases.
- **Empliq™ Amniotic tissue product ranges** -- Three amniotic tissue product ranges used to aid the healing of wounds.

### *In development*

- **NervAlign® Nerve Conduit Range** – Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
- **NervAlign® Nerve Guide Matrix** – a customised and ready-to-use alternative to existing nerve grafts, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

## Market Leadership and Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching \$271k in sales and YTD FY2026 sales revenues showing further significant increases across its portfolio. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US\$1.6 billion in 2024 and is projected to reach \$6.2 billion by 2031.<sup>2</sup>

## Vision and Values

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.

---

<sup>2</sup> Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)